Hydralazine: Difference between revisions
(peds dose) |
|||
| (13 intermediate revisions by 6 users not shown) | |||
| Line 5: | Line 5: | ||
==Adult Dosing== | ==Adult Dosing== | ||
* | *hypertension: 10 - 50mg PO QID | ||
* Hypertensive crisis: 10- | *Hypertensive crisis: 10-20mg IM/IV q2-4h | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Hypertensive Crisis: | *Hypertensive Crisis: | ||
# 1 mo - 12 years: 0.1 - 0. | #1 mo - 12 years: 0.1 - 0.5mg/kg IM/IV q4-6h, max dose of 20mg | ||
# > 12 years old: 10 - | #> 12 years old: 10 - 20mg IV q2-4h | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*Lactation: | *Lactation: Probably Safe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult: CrCl 10-50: give q8h, CrCl <10, give q8-16h | ||
**Pediatric | **Pediatric: CrCl 10-50: give q8h, CrCl <10, give q8-16h | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult: not defined | ||
**Pediatric | **Pediatric: not defined | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*mitral valvular rheumatic heart disease | |||
*Caution if renal impairment | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*MI | |||
*neutropenia | |||
*lupus erythematosus (SLE) | |||
*peripheral neuritis | |||
===Common=== | ===Common=== | ||
*headache | |||
*tachycardia | |||
*angina | |||
*nausea/vomiting | |||
*rash | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 3-7 hours | ||
*Metabolism: | *Metabolism: liver | ||
*Excretion: | *Excretion: urine, feces | ||
*Mechanism of Action: | *Mechanism of Action: directly dilates peripheral vessels | ||
==See Also== | ==See Also== | ||
==References== | |||
<references/> | <references/> | ||
[[Category: | |||
[[Category:Pharmacology]] | |||
[[Category:Cardiology]] | |||
Latest revision as of 06:11, 20 August 2022
General
- Type: Vasodilator
- Dosage Forms: 10, 25, 50, 100; PO, IM, IV
- Common Trade Names: Apresoline
Adult Dosing
- hypertension: 10 - 50mg PO QID
- Hypertensive crisis: 10-20mg IM/IV q2-4h
Pediatric Dosing
- Hypertensive Crisis:
- 1 mo - 12 years: 0.1 - 0.5mg/kg IM/IV q4-6h, max dose of 20mg
- > 12 years old: 10 - 20mg IV q2-4h
Special Populations
- Pregnancy Rating: C
- Lactation: Probably Safe
- Renal Dosing
- Adult: CrCl 10-50: give q8h, CrCl <10, give q8-16h
- Pediatric: CrCl 10-50: give q8h, CrCl <10, give q8-16h
- Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- mitral valvular rheumatic heart disease
- Caution if renal impairment
Adverse Reactions
Serious
- MI
- neutropenia
- lupus erythematosus (SLE)
- peripheral neuritis
Common
- headache
- tachycardia
- angina
- nausea/vomiting
- rash
Pharmacology
- Half-life: 3-7 hours
- Metabolism: liver
- Excretion: urine, feces
- Mechanism of Action: directly dilates peripheral vessels